Desai Antal Rohit

Director Desai Antal Rohit bought 426,262 shares for $10,482,942.95 across 7 transactions at PRCT, now down 61.2% from 52-week high.

Desai Antal Rohit, a Director at PROCEPT BioRobotics, executed 7 separate purchases totaling 426,262 shares for $10,482,942.95 between March 5–9, 2026, at a blended average price of $24.59. The stock is now trading at $25.26, only 2.7% above his average acquisition price, but stands -61.2% below its 52-week high of $65.05 and has declined -27.8% over the past 90 days. Desai's prior track record at PRCT shows 5 consecutive sells in June 2025 that were well-timed at the 90-day mark, all preceding further declines—a pattern suggesting he exits positions before weakness materializes. This substantial purchase into a stock that has lost nearly two-thirds of its recent peak, after proven expertise at identifying sell signals, warrants attention to whether this represents a contrarian conviction or signals internal assessment of value at depressed levels. The company is unprofitable (net income: $-21.4M) against revenue of $83.3M, though it is growing at +37.2% annually.

Director Desai sold 75,000 shares (83.9% of holdings) for $4.7M across 8 transactions, leaving 14,363 shares post-sale at blended $62.93 avg price.

Desai, a Director at PROCEPT BioRobotics, executed 8 separate sales totaling 75,000 shares for $4,719,492.35 over three trading days (June 10–12, 2025), reducing his holdings from 89,363 shares to 14,363 shares (an 83.9% reduction). The blended average sale price was $62.93, executed when the stock was trading near recent strength after a 30-day gain of +15.3%. The company reported latest-quarter revenue of $69,162,000.00 but posted a net loss of $-24,737,000.00, with negative full-year net income despite 64.8% annual revenue growth, underscoring continued unprofitability at a $3.4B market cap. His cross-ticker track record shows 20 prior sells with a 90d well-timed rate of 100.00%, but at this specific ticker (PRCT), he has 5 recent prior sales on 2025-06-05 with outcomes not yet measurable, providing no baseline for comparing this sale's positioning relative to his PRCT-specific history.

Director Desai sold 75,000 shares (45.6% of holdings) for $4.7M on 2025-06-03 to -06-05; PRCT 5-of-5 prior sells well-timed at 90-day mark.

Desai Antal Rohit (Director) executed 13 separate sales totaling 75,000 shares for $4,661,861.00 over June 3–5, reducing his position from 164,363 shares to 89,363 shares. The blended average price across all transactions was $62.16, occurring when the stock was trading in a range from $58.04 to $66.73 and currently sits at $65.05 (down 34.6% from its 52-week high of $99.45). Notably, his prior 5 sales at PRCT all proved well-timed at the 90-day mark, with each generating negative 90-day returns of -21.8% to -25.2%, suggesting a consistent pattern of selling before subsequent declines. The company remains unprofitable (net income $-24.7M on $69.2M quarterly revenue) despite 64.8% annual revenue growth, making near-term price momentum uncertain; the insider's exit of 45.6% of holdings against this backdrop warrants investor attention to whether this signals internal forward-looking concerns.

Director Rohit Desai sold 100,000 shares (100.0K shares) for $9,633,437.75 across 3 days at blended $96.33, reducing stake 37.8%

Rohit Desai, a Director at PROCEPT BioRobotics, executed 12 separate sales totaling 100,000 shares for $9,633,437.75 ($9.6M) on 2024-11-05 through 2024-11-07 at an average price of $96.33, reducing his holdings from 264,363 shares (264.4K shares) to 164,363 shares (164.4K shares)—a 37.8% reduction. The stock currently trades at $96.23, within 2.0% of the 52-week high of $98.23. Prior sales by this insider at PRCT (5 trades on 2024-09-11 and 2024-09-12) recorded 30-day returns of -7.0% to -11.1%, and the insider's cross-ticker historical record shows 20 prior sells with an average 30-day return of -6.0%, establishing a pattern of selling near local peaks. The company reported $58,370,000 in latest-quarter revenue with a net loss of $20,974,000, yet shows 81.6% annual revenue growth and a $5.0B market cap, positioning it as a high-growth but currently unprofitable enterprise where insider selling at elevated valuations merits tracking.

Director Desai sold 120,065 shares for $9.4M across 10 transactions (Sept 10-12); holdings reduced 37.8% to 197.5K shares.

Desai Antal Rohit, a Director at PROCEPT BioRobotics, executed 10 separate sales totaling 120,065 shares for $9,375,594.85 between September 10–12, 2024, at prices ranging from $75.78 to $80.65 (blended average $78.09). This sale reduced his holdings from 317,518 shares to 197,453 shares, a 37.8% reduction in position size. The timing coincides with the stock trading near its 52-week high of $83.44 (current price $80.39 is 3.7% below that peak), and the company has demonstrated strong 81.6% annual revenue growth but remains unprofitable with a net loss of $25.6M over its most recent full fiscal year. The director's recent prior sales at PRCT (5 trades on Sept 4–5) suggest an ongoing disposition pattern in the same period; however, those earlier outcomes are not yet measurable. This concentrated multi-day liquidation of over one-third of holdings during a period of elevated valuation and continued operating losses warrants investor attention to whether management view of medium-term prospects has shifted.

Director Desai sells 102,157 shares at blended avg $75.78 over 3 days for $7.7M; retains 317.5K shares post-sale

Desai Antal Rohit (Director) executed 13 separate sales totaling 102,157 shares for $7,741,893.11 across September 3–5, 2024, at prices ranging from $74.90 to $78.00 and a blended average price of $75.78. This represents a 24.3% reduction in his shareholding, from 419.7K to 317.5K shares. The sales occurred during a period when the stock was trading within its 52-week range but down 8.5% from its 52-week high of $83.44, and they followed a strong 26.0% gain in the preceding 30 days. The company is currently unprofitable (net income of $-25.6M in the latest quarter), despite reporting robust annual revenue growth of 81.6%; the combination of aggressive growth but negative profitability, coupled with a substantial reduction in director holdings at a price below the recent 52-week peak, merits attention in context of the company's path to profitability.